U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07388875) titled 'Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC' on Jan. 21.
Brief Summary: This is a Phase II, single-arm, open-label clinical study to evaluate the efficacy and safety of Sacituzumab Tirumotecan (SKB264) combined with Anlotinib in patients with extensive-stage small cell lung cancer (ES-SCLC). The study is designed for patients who have experienced disease progression or treatment failure after prior first-line therapy with a PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy. The primary hypothesis is that this combination therapy will improve the objective response rate compared to historical...